Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study

被引:1065
作者
Cohen, Alexander T. [1 ]
Tapson, Victor F. [2 ]
Bergmann, Jean-Francois [3 ]
Goldhaber, Samuel Z. [4 ]
Kakkar, Ajay K. [5 ]
Deslandes, Bruno [6 ]
Huang, Wei [7 ]
Zayaruzny, Maksim [7 ]
Emery, Leigh [7 ]
Anderson, Frederick A., Jr. [7 ]
机构
[1] Kings Coll Hosp London, London SE5 9RS, England
[2] Duke Univ, Med Ctr, Durham, NC USA
[3] Univ Paris 07, Hop Lariboisiere, Paris, France
[4] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA
[5] Barts & London Queen Marys Sch Med & Dent, Thrombosis Res Inst, London, England
[6] Sanofi Aventis, Paris, France
[7] Univ Massachusetts, Sch Med, Ctr Outcomes Res, Worcester, MA USA
关键词
D O I
10.1016/S0140-6736(08)60202-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background information about the variation in the risk for venous thromboembolism (VTE) and in prophylaxis practices around the world is scarce. The ENDORSE (Epidemiologic International Day for the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Setting) study is a multinational cross-sectional survey designed to assess the prevalence of VTE risk in the acute hospital care setting, and to determine the proportion of at-risk patients who receive effective prophylaxis. Methods All hospital inpatients aged 40 years or over admitted to a medical ward, or those aged 18 years or over admitted to a surgical ward, in 358 hospitals across 32 countries were assessed for risk of VTE on the basis of hospital chart review. The 2004 American College of Chest Physicians (ACCP) evidence-based consensus guidelines were used to assess VTE risk and to determine whether patients were receiving recommended prophylaxis. Findings 68183 patients were enrolled; 30 827 (45%) were categorised as surgical, and 37 356 (55%) as medical. On the basis of ACCP criteria, 35 329 (51.8%; 95% CI 51.4-52.2; between-country range 35.6-72.6) patients were judged to be at risk for VTE, including 19 842 (64.4%; 63.8-64.9; 44.1-80.2) surgical patients and 15 487 (41. 5%; 41.0-42. 0; 21.1-71.2) medical patients. Of the surgical patients at risk, 11613 (58.5%; 57.8-59.2; 0.2-92.1) received ACCP-recommended VTE prophylaxis, compared with 6119 (39.5%; 38.7-40.3; 3.1-70.4) at-risk medical patients. Interpretation A large proportion of hospitalised patients are at risk for VTE, but there is a low rate of appropriate prophylaxis. Our data reinforce the rationale for the use of hospital-wide strategies to assess patients' VTE risk and to implement measures that ensure that at-risk patients receive appropriate prophylaxis.
引用
收藏
页码:387 / 394
页数:8
相关论文
共 22 条
  • [1] Fatal pulmonary embolism in hospitalised patients: a necropsy review
    Alikhan, R
    Peters, F
    Wilmott, R
    Cohen, AT
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (12) : 1254 - 1257
  • [2] Thromboprophylaxis rates in US medical centers: success or failure?
    Amin, A.
    Stemkowski, S.
    Lin, J.
    Yang, G.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (08) : 1610 - 1616
  • [3] Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism
    Anderson, Frederick A., Jr.
    Zayaruzny, Maxim
    Helt, John A.
    Fidan, Dogan
    Cohen, Alexander T.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (09) : 777 - 782
  • [4] Guidelines on the use and monitoring of heparin
    Baglin, T
    Barrowcliffe, TW
    Cohen, A
    Greaves, M
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 (01) : 19 - 34
  • [5] CLAGETT GP, 1992, CHEST S, V102, P391
  • [6] Venous thromboembolism (VTE) in Europe - The number of VTE events and associated morbidity and mortality
    Cohen, Alexander T.
    Agnelli, Giancarlo
    Anderson, Frederick A.
    Arcelus, Juan I.
    Bergqvist, David
    Brecht, Josef G.
    Greer, Ian A.
    Heit, John A.
    Hutchinson, Julia L.
    Kakkar, Ajay K.
    Mottier, Dominique
    Oger, Emmanuel
    Samama, Meyer-Michel
    Spannagl, Michael
    [J]. THROMBOSIS AND HAEMOSTASIS, 2007, 98 (04) : 756 - 764
  • [7] Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial
    Cohen, AT
    Davidson, BL
    Gallus, AS
    Lassen, MR
    Prins, MH
    Tomkowski, W
    Turpie, AGG
    Egberts, JFM
    Lensing, AWA
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2006, 332 (7537): : 325 - 327
  • [8] Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients
    Cohen, AT
    Alikhan, R
    Arcelus, JI
    Bergmann, JF
    Haass, S
    Merli, G
    Spyropoulos, AC
    Tapson, VF
    Turpie, AGG
    [J]. THROMBOSIS AND HAEMOSTASIS, 2005, 94 (04) : 750 - 759
  • [9] Eikelboom JW, 2004, HAEMATOLOGICA, V89, P586
  • [10] Prevention of venous thromboembolism
    Geerts, WH
    Pineo, GF
    Heit, JA
    Bergqvist, D
    Lassen, MR
    Colwell, CW
    Ray, JG
    [J]. CHEST, 2004, 126 (03) : 338S - 400S